Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial
No Thumbnail Available
Identifiers
Date
2020-05-01
Authors
Ciruelos, E. M.
Villagrasa, P.
Oliveira, M.
Pernas Simon, S.
Cortes, J.
Vazquez, S.
Martinez, N.
Perello, A.
Bermejo De Las Heras, B.
Martinez, E.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
